English

Dare Bioscience, Inc.

EDGAR

CERU Registration statement (S-1) · filed 2026-08-26

Annual consolidated revenue for 2025: about USD 1.03M, using the latest reported figures. The previous period, 2024, was about USD 9.784K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

188 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 187546 USD Source

Operating margin

-1,582.53%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -2967980 USD Source
Revenue: 187546 USD Source

Operating cash flow

-6.78 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -12295690 USD Source
Operating Cash Flow: -5520644 USD Source

Free cash flow

-6.86 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -12295690 USD Source
Operating Cash Flow: -5520644 USD Source
Capital Expenditure: 80586 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 12.6 million USD 2026-06-30 Source
Exact value

12600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 15.2 million shares 2026-06-30 Source
Exact value

15169502 shares

Reported share-count change

67.98% · 6.14 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

9030386 shares · 2025-06-30· Source
15169502 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.37 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 2262 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 1030193 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 6517 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 152455 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 187546 USD · 2026-04-01 – 2026-06-30 Source

Net income

-10.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -3562766 USD · 2025-07-01 – 2025-09-30 Source
Net income: -13400000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -12000000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -2999889 USD · 2026-01-01 – 2026-03-31 Source
Net income: -2982773 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-11.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -11330134 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10887999 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -9885870 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -11330134 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5520644 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -12295690 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -5520644 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

462 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 178637 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3935 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 385278 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 178637 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 80586 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-11.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -11330134 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10887999 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -9885870 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -11330134 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5520644 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -12295690 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -5520644 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 178637 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3935 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 385278 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 178637 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 80586 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+10,429.4%

Prior period

USD 9,784

2024-01-01 – 2024-12-31
Current period

USD 1.03 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1030193 − 9784 = 1020409 USD

9784 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1030193 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Year-over-year change in Revenue: 1020409 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1030193 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1633601 Filing: 000140191426000004 Input fundies:Revenue: 9784 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1634260 Filing: 000140191426000004
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 9.35 million

Prior period

−USD 4.05 million

2024-01-01 – 2024-12-31
Current period

−USD 13.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-13400000 − -4053599 = -9346401 USD

-4053599 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-13400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Year-over-year change in Net income: -9346401 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -13400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1804001 Filing: 000140191426000004 Input fundies:NetIncome: -4053599 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1717706 Filing: 000140191426000004
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-280.6%

Prior period

USD 5.47 million

2024-01-01 – 2024-12-31
Current period

−USD 9.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-9885870 − 5473555 = -15359425 USD

5473555 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-9885870 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Year-over-year change in Operating cash flow: -15359425 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -9885870 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1744604 Filing: 000140191426000004 Input fundies:OperatingCashFlow: 5473555 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1745252 Filing: 000140191426000004
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-32.8%

Prior period

USD 573,046

2024-01-01 – 2024-12-31
Current period

USD 385,278

2025-01-01 – 2025-12-31

Exact inputs and evidence

385278 − 573046 = -187768 USD

573046 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
385278 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Year-over-year change in Capital expenditure: -187768 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 385278 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1746578 Filing: 000140191426000004 Input fundies:CapitalExpenditure: 573046 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1747164 Filing: 000140191426000004
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 1.03 million 100% of revenue
Cost of revenue USD 295,799 29% of revenue
Operating expenses USD 14.29 million 1,387% of revenue
Operating income −USD 13.55 million −1,316% of revenue
Tax, interest and other Derived −USD 152,334 −15% of revenue
Net income −USD 13.4 million −1,301% of revenue

Cash

Operating cash flow −USD 9.89 million −960% of revenue
Capital expenditure USD 385,278 37% of revenue
Free cash flow Derived −USD 10.27 million −997% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 182% of revenue.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 414% of revenue.
2023 Operating loss: operating costs were 1,202% of revenue.
2024 Operating loss: operating costs were 239,792% of revenue.
2025 Operating loss: operating costs were 1,416% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	766000	1396591 Derived	-630591	42096 Derived	-672687	-907299 Derived	Source 2016-01-01 – 2016-12-31: 766000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -630591 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -672687 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -372299 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 535000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	39068512 Derived	-39068512	-372407 Derived	-38696105	-28778561 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -39068512 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -38696105 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -28764037 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 14524 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	10000000	41385488 Derived	-31385488	-437750 Derived	-30947738	-18151498 Derived	Source 2022-01-01 – 2022-12-31: 10000000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -31385488 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -30947738 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -18088429 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 63069 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	2807885	33747765 Derived	-30939880	-778489 Derived	-30161391	-39486084 Derived	Source 2023-01-01 – 2023-12-31: 2807885 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -30939880 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -30161391 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -38856654 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 629430 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	9784	23461269 Derived	-23451485	-19397886 Derived	-4053599	4900509 Derived	Source 2024-01-01 – 2024-12-31: 9784 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -23451485 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -4053599 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 5473555 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 573046 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1030193	14582527 Derived	-13552334	-152334 Derived	-13400000	-10271148 Derived	Source 2025-01-01 – 2025-12-31: 1030193 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -13552334 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -13400000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -9885870 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 385278 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	766000	Revenue: 766000 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	10000000	Revenue: 10000000 Open source
20232023-12-31	Revenue	2807885	Revenue: 2807885 Open source
20242024-12-31	Revenue	9784	Revenue: 9784 Open source
20252025-12-31	Revenue	1030193	Revenue: 1030193 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

10,429.4% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 766000 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 10000000 Open source Revenue: 0 Open source
20232023-12-31	Year over year	-71.9%	Revenue: 2807885 Open source Revenue: 10000000 Open source
20242024-12-31	Year over year	-99.7%	Revenue: 9784 Open source Revenue: 2807885 Open source
20252025-12-31	Year over year	10,429.4%	Revenue: 1030193 Open source Revenue: 9784 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,315.5% 2025

Net margin -1,300.7% 2025

Free cash flow margin -997% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-82.3%	Operating Income: -630591 Open source Revenue: 766000 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -39068512 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	-313.9%	Operating Income: -31385488 Open source Revenue: 10000000 Open source
20232023-12-31	Operating margin	-1,101.9%	Operating Income: -30939880 Open source Revenue: 2807885 Open source
20242024-12-31	Operating margin	-239,692.2%	Operating Income: -23451485 Open source Revenue: 9784 Open source
20252025-12-31	Operating margin	-1,315.5%	Operating Income: -13552334 Open source Revenue: 1030193 Open source
20162016-12-31	Net margin	-87.8%	Net Income: -672687 Open source Revenue: 766000 Open source
20212021-12-31	Net margin	Not reported	Net Income: -38696105 Open source Revenue: 0 Open source
20222022-12-31	Net margin	-309.5%	Net Income: -30947738 Open source Revenue: 10000000 Open source
20232023-12-31	Net margin	-1,074.2%	Net Income: -30161391 Open source Revenue: 2807885 Open source
20242024-12-31	Net margin	-41,430.9%	Net Income: -4053599 Open source Revenue: 9784 Open source
20252025-12-31	Net margin	-1,300.7%	Net Income: -13400000 Open source Revenue: 1030193 Open source
20162016-12-31	Free cash flow margin	-118.4%	Revenue: 766000 Open source Operating Cash Flow: -372299 Open source Capital Expenditure: 535000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -28764037 Open source Capital Expenditure: 14524 Open source
20222022-12-31	Free cash flow margin	-181.5%	Revenue: 10000000 Open source Operating Cash Flow: -18088429 Open source Capital Expenditure: 63069 Open source
20232023-12-31	Free cash flow margin	-1,406.3%	Revenue: 2807885 Open source Operating Cash Flow: -38856654 Open source Capital Expenditure: 629430 Open source
20242024-12-31	Free cash flow margin	50,087%	Revenue: 9784 Open source Operating Cash Flow: 5473555 Open source Capital Expenditure: 573046 Open source
20252025-12-31	Free cash flow margin	-997%	Revenue: 1030193 Open source Operating Cash Flow: -9885870 Open source Capital Expenditure: 385278 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -9.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-372299	Operating Cash Flow: -372299 Open source
20212021-12-31	Operating cash flow	-28764037	Operating Cash Flow: -28764037 Open source
20222022-12-31	Operating cash flow	-18088429	Operating Cash Flow: -18088429 Open source
20232023-12-31	Operating cash flow	-38856654	Operating Cash Flow: -38856654 Open source
20242024-12-31	Operating cash flow	5473555	Operating Cash Flow: 5473555 Open source
20252025-12-31	Operating cash flow	-9885870	Operating Cash Flow: -9885870 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -10.3M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-907299	Operating Cash Flow: -372299 Open source Capital Expenditure: 535000 Open source
20212021-12-31	Free cash flow	-28778561	Operating Cash Flow: -28764037 Open source Capital Expenditure: 14524 Open source
20222022-12-31	Free cash flow	-18151498	Operating Cash Flow: -18088429 Open source Capital Expenditure: 63069 Open source
20232023-12-31	Free cash flow	-39486084	Operating Cash Flow: -38856654 Open source Capital Expenditure: 629430 Open source
20242024-12-31	Free cash flow	4900509	Operating Cash Flow: 5473555 Open source Capital Expenditure: 573046 Open source
20252025-12-31	Free cash flow	-10271148	Operating Cash Flow: -9885870 Open source Capital Expenditure: 385278 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

91.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	1,692.8%	Total Liabilities: 755235 Open source Total Assets: 44614 Open source
20212021-12-31	Liabilities / assets	30.6%	Total Liabilities: 17052856 Open source Total Assets: 55807177 Open source
20222022-12-31	Liabilities / assets	74.6%	Total Liabilities: 32714273 Open source Total Assets: 43826383 Open source
20232023-12-31	Liabilities / assets	123.7%	Total Liabilities: 26329855 Open source Total Assets: 21282215 Open source
20242024-12-31	Liabilities / assets	127.2%	Total Liabilities: 28113220 Open source Total Assets: 22101131 Open source
20252025-12-31	Liabilities / assets	91.2%	Total Liabilities: 29631929 Open source Total Assets: 32474563 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.14× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	0.06×	Current Assets: 44614 Open source Current Liabilities: 755235 Open source
20212021-12-31	Current assets / current liabilities	3.44×	Current Assets: 55296016 Open source Current Liabilities: 16052856 Open source
20222022-12-31	Current assets / current liabilities	1.36×	Current Assets: 43038753 Open source Current Liabilities: 31623927 Open source
20232023-12-31	Current assets / current liabilities	0.86×	Current Assets: 17543539 Open source Current Liabilities: 20480436 Open source
20242024-12-31	Current assets / current liabilities	0.85×	Current Assets: 18447863 Open source Current Liabilities: 21613067 Open source
20252025-12-31	Current assets / current liabilities	1.14×	Current Assets: 27063879 Open source Current Liabilities: 23685687 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 672,687 Exact value Exact value: -672687 USD 2016-01-01 – 2016-12-31: -672687 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2016-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -672687 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -672687 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000156459018006989/dare-20171231.xml#88760 Filing: 000156459018006989 The citation records this snapshot. The page link may show a newer release later.	−USD 372,299 Exact value Exact value: -372299 USD 2016-01-01 – 2016-12-31: -372299 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2016-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -372299 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -372299 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000156459018006989/dare-20171231.xml#102667 Filing: 000156459018006989 The citation records this snapshot. The page link may show a newer release later.	USD 535,000 Exact value Exact value: 535000 USD 2016-01-01 – 2016-12-31: 535000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2016-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 535000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 535000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000119312517202472/ceru-20161231.xml#383164 Filing: 000119312517202472 The citation records this snapshot. The page link may show a newer release later.	−USD 907,299 Calculation and evidence -372299 − 535000 USD Exact free cash flow: -907299 USD 2016-01-01 – 2016-12-31: -372299 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 535000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2016-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -907299 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -372299 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000156459018006989/dare-20171231.xml#102667 Filing: 000156459018006989 Input fundies:CapitalExpenditure: 535000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000119312517202472/ceru-20161231.xml#383164 Filing: 000119312517202472 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 11.5 million Exact value Exact value: -11503117 USD 2017-01-01 – 2017-12-31: -11503117 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2017-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -11503117 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11503117 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/dare-20181231.xml#180510 Filing: 000140191419000015 The citation records this snapshot. The page link may show a newer release later.	−USD 2.54 million Exact value Exact value: -2540128 USD 2017-01-01 – 2017-12-31: -2540128 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2017-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -2540128 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2540128 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/dare-20181231.xml#179837 Filing: 000140191419000015 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2017-01-01 – 2017-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2017-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/dare-20181231.xml#188181 Filing: 000140191419000015 The citation records this snapshot. The page link may show a newer release later.	−USD 2.54 million Calculation and evidence -2540128 − 0 USD Exact free cash flow: -2540128 USD 2017-01-01 – 2017-12-31: -2540128 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2017-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -2540128 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2540128 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/dare-20181231.xml#179837 Filing: 000140191419000015 Input fundies:CapitalExpenditure: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/dare-20181231.xml#188181 Filing: 000140191419000015 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 16.74 million Exact value Exact value: -16738815 USD 2018-01-01 – 2018-12-31: -16738815 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2018-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -16738815 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16738815 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/dare-20191231.xml#174555 Filing: 000140191420000042 The citation records this snapshot. The page link may show a newer release later.	−USD 10.27 million Exact value Exact value: -10268425 USD 2018-01-01 – 2018-12-31: -10268425 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2018-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -10268425 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10268425 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/dare-20191231.xml#173881 Filing: 000140191420000042 The citation records this snapshot. The page link may show a newer release later.	USD 11,836 Exact value Exact value: 11836 USD 2018-01-01 – 2018-12-31: 11836 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2018-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 11836 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11836 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/dare-20191231.xml#182945 Filing: 000140191420000042 The citation records this snapshot. The page link may show a newer release later.	−USD 10.28 million Calculation and evidence -10268425 − 11836 USD Exact free cash flow: -10280261 USD 2018-01-01 – 2018-12-31: -10268425 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 11836 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2018-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -10280261 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10268425 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/dare-20191231.xml#173881 Filing: 000140191420000042 Input fundies:CapitalExpenditure: 11836 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/dare-20191231.xml#182945 Filing: 000140191420000042 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 14.26 million Exact value Exact value: -14263830 USD 2019-01-01 – 2019-12-31: -14263830 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2019-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -14263830 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14263830 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191421000041/dare-20201231.htm#1566107 Filing: 000140191421000041 The citation records this snapshot. The page link may show a newer release later.	−USD 13.32 million Exact value Exact value: -13315480 USD 2019-01-01 – 2019-12-31: -13315480 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2019-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -13315480 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13315480 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191421000041/dare-20201231.htm#1592920 Filing: 000140191421000041 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2019-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191421000041/dare-20201231.htm#1597685 Filing: 000140191421000041 The citation records this snapshot. The page link may show a newer release later.	−USD 13.32 million Calculation and evidence -13315480 − 0 USD Exact free cash flow: -13315480 USD 2019-01-01 – 2019-12-31: -13315480 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2019-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -13315480 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13315480 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191421000041/dare-20201231.htm#1592920 Filing: 000140191421000041 Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191421000041/dare-20201231.htm#1597685 Filing: 000140191421000041 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 27.4 million Exact value Exact value: -27400743 USD 2020-01-01 – 2020-12-31: -27400743 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2020-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -27400743 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27400743 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/dare-20211231.htm#1450292 Filing: 000140191422000032 The citation records this snapshot. The page link may show a newer release later.	−USD 25.23 million Exact value Exact value: -25234924 USD 2020-01-01 – 2020-12-31: -25234924 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2020-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -25234924 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25234924 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/dare-20211231.htm#1479554 Filing: 000140191422000032 The citation records this snapshot. The page link may show a newer release later.	USD 17,625 Exact value Exact value: 17625 USD 2020-01-01 – 2020-12-31: 17625 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2020-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 17625 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17625 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/dare-20211231.htm#1482211 Filing: 000140191422000032 The citation records this snapshot. The page link may show a newer release later.	−USD 25.25 million Calculation and evidence -25234924 − 17625 USD Exact free cash flow: -25252549 USD 2020-01-01 – 2020-12-31: -25234924 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 17625 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2020-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -25252549 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25234924 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/dare-20211231.htm#1479554 Filing: 000140191422000032 Input fundies:CapitalExpenditure: 17625 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/dare-20211231.htm#1482211 Filing: 000140191422000032 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 38.7 million Exact value Exact value: -38696105 USD 2021-01-01 – 2021-12-31: -38696105 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2021-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -38696105 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38696105 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231.htm#1466542 Filing: 000140191423000013 The citation records this snapshot. The page link may show a newer release later.	−USD 28.76 million Exact value Exact value: -28764037 USD 2021-01-01 – 2021-12-31: -28764037 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2021-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -28764037 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28764037 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231.htm#1487497 Filing: 000140191423000013 The citation records this snapshot. The page link may show a newer release later.	USD 14,524 Exact value Exact value: 14524 USD 2021-01-01 – 2021-12-31: 14524 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2021-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 14524 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14524 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231.htm#1489535 Filing: 000140191423000013 The citation records this snapshot. The page link may show a newer release later.	−USD 28.78 million Calculation and evidence -28764037 − 14524 USD Exact free cash flow: -28778561 USD 2021-01-01 – 2021-12-31: -28764037 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 14524 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2021-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -28778561 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28764037 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231.htm#1487497 Filing: 000140191423000013 Input fundies:CapitalExpenditure: 14524 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231.htm#1489535 Filing: 000140191423000013 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 30.95 million Exact value Exact value: -30947738 USD 2022-01-01 – 2022-12-31: -30947738 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2022-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -30947738 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30947738 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231.htm#1510926 Filing: 000140191424000016 The citation records this snapshot. The page link may show a newer release later.	−USD 18.09 million Exact value Exact value: -18088429 USD 2022-01-01 – 2022-12-31: -18088429 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2022-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -18088429 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18088429 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231.htm#1530170 Filing: 000140191424000016 The citation records this snapshot. The page link may show a newer release later.	USD 63,069 Exact value Exact value: 63069 USD 2022-01-01 – 2022-12-31: 63069 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2022-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 63069 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 63069 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231.htm#1532139 Filing: 000140191424000016 The citation records this snapshot. The page link may show a newer release later.	−USD 18.15 million Calculation and evidence -18088429 − 63069 USD Exact free cash flow: -18151498 USD 2022-01-01 – 2022-12-31: -18088429 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 63069 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2022-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -18151498 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18088429 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231.htm#1530170 Filing: 000140191424000016 Input fundies:CapitalExpenditure: 63069 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231.htm#1532139 Filing: 000140191424000016 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 30.16 million Exact value Exact value: -30161391 USD 2023-01-01 – 2023-12-31: -30161391 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2023-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -30161391 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30161391 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm#1716184 Filing: 000140191425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 38.86 million Exact value Exact value: -38856654 USD 2023-01-01 – 2023-12-31: -38856654 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2023-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -38856654 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -38856654 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm#1739705 Filing: 000140191425000012 The citation records this snapshot. The page link may show a newer release later.	USD 629,430 Exact value Exact value: 629430 USD 2023-01-01 – 2023-12-31: 629430 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2023-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 629430 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 629430 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm#1741675 Filing: 000140191425000012 The citation records this snapshot. The page link may show a newer release later.	−USD 39.49 million Calculation and evidence -38856654 − 629430 USD Exact free cash flow: -39486084 USD 2023-01-01 – 2023-12-31: -38856654 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 629430 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2023-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -39486084 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38856654 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm#1739705 Filing: 000140191425000012 Input fundies:CapitalExpenditure: 629430 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm#1741675 Filing: 000140191425000012 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.05 million Exact value Exact value: -4053599 USD 2024-01-01 – 2024-12-31: -4053599 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2024-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -4053599 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4053599 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1717706 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	USD 5.47 million Exact value Exact value: 5473555 USD 2024-01-01 – 2024-12-31: 5473555 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2024-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: 5473555 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5473555 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1745252 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	USD 573,046 Exact value Exact value: 573046 USD 2024-01-01 – 2024-12-31: 573046 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2024-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 573046 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 573046 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1747164 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	USD 4.9 million Calculation and evidence 5473555 − 573046 USD Exact free cash flow: 4900509 USD 2024-01-01 – 2024-12-31: 5473555 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 573046 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2024-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: 4900509 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5473555 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1745252 Filing: 000140191426000004 Input fundies:CapitalExpenditure: 573046 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1747164 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 13.4 million Exact value Exact value: -13400000 USD 2025-01-01 – 2025-12-31: -13400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Net Income: -13400000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1804001 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	−USD 9.89 million Exact value Exact value: -9885870 USD 2025-01-01 – 2025-12-31: -9885870 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Operating Cash Flow: -9885870 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9885870 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1744604 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	USD 385,278 Exact value Exact value: 385278 USD 2025-01-01 – 2025-12-31: 385278 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Capital Expenditure: 385278 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 385278 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1746578 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.	−USD 10.27 million Calculation and evidence -9885870 − 385278 USD Exact free cash flow: -10271148 USD 2025-01-01 – 2025-12-31: -9885870 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 385278 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dare Bioscience, Inc. · 2025-12-31 Dare Bioscience, Inc. (edgar:1401914) Free cash flow: -10271148 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:50:44Z Snapshot: 7ac50143acc79cb46c19fbe768dc2cb647008b39b779b1202dea7bf7283914f8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1401914?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9885870 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1744604 Filing: 000140191426000004 Input fundies:CapitalExpenditure: 385278 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm#1746578 Filing: 000140191426000004 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

70 filings · 3,036 latest values · 3,035 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001401914, 1401914, CERU, DARE, edgar:1401914

Also known as CERULEAN PHARMA INC., Cerulean Pharma Inc., DARE BIOSCIENCE, INC., DARÉ BIOSCIENCE, INC., Dare Bioscience, Inc., Tempo Pharmaceuticals Inc

Dare Bioscience, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation